These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Aaltonen KJ; Ylikylä S; Tuulikki Joensuu J; Isomäki P; Pirilä L; Kauppi M; Rannio T; Eklund K; Blom M; Nordström D Rheumatology (Oxford); 2017 May; 56(5):725-735. PubMed ID: 28064209 [TBL] [Abstract][Full Text] [Related]
26. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. Sullivan SD; Alfonso-Cristancho R; Carlson J; Mallya U; Ringold S J Med Econ; 2013; 16(3):391-6. PubMed ID: 23298329 [TBL] [Abstract][Full Text] [Related]
27. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis. Vanderpoel J; Tkacz J; Brady BL; Ellis L Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662 [TBL] [Abstract][Full Text] [Related]
28. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ; Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186 [TBL] [Abstract][Full Text] [Related]
31. Switching biologics in the treatment of psoriatic arthritis. Merola JF; Lockshin B; Mody EA Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434 [TBL] [Abstract][Full Text] [Related]
32. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056 [TBL] [Abstract][Full Text] [Related]
33. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C; Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098 [TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Hochberg MC; Tracy JK; Hawkins-Holt M; Flores RH Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823 [TBL] [Abstract][Full Text] [Related]
36. Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. Wells AF; Curtis JR; Betts KA; Douglas K; Du EX; Ganguli A Clin Ther; 2017 Aug; 39(8):1680-1694.e2. PubMed ID: 28734661 [TBL] [Abstract][Full Text] [Related]
37. Advances in use of immunomodulatory agents--a rheumatology perspective. Her M; Kavanaugh A Nat Rev Gastroenterol Hepatol; 2015 Jun; 12(6):363-8. PubMed ID: 25895821 [TBL] [Abstract][Full Text] [Related]
38. Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Tanaka Y; Hirata S Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736 [TBL] [Abstract][Full Text] [Related]
39. Evidence that cytokines play a role in rheumatoid arthritis. Brennan FM; McInnes IB J Clin Invest; 2008 Nov; 118(11):3537-45. PubMed ID: 18982160 [TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Carubbi F; Zugaro L; Cipriani P; Conchiglia A; Gregori L; Danniballe C; Letizia Pistoia M; Liakouli V; Ruscitti P; Ciccia F; Triolo G; Masciocchi C; Giacomelli R Int J Immunopathol Pharmacol; 2016 Jun; 29(2):252-66. PubMed ID: 26684633 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]